2H 2018 Life Sciences Software Market Update
Madison Park Group (MPG) actively tracks the life sciences software landscape and has been instrumental in strategic deals across the drug development & commercial spectrum.
Through MPG’s time in the space, we’ve noticed a number of trends and developments:
- Continued increase in pharma R&D spend coupled with a need to optimize trial costs and ROI provides ample market opportunity for clinical trial software vendors
- Convergence of software, data and analytical tools to optimize life sciences decision-making, especially through the use of Real World Evidence
- Pre-clinical vendors continue to capitalize on Standard for the Exchange of Nonclinical Data (SEND) regulations through both software and outsourced services